M Cazzola

Summary

Affiliation: Unit of Pneumology and Allergology
Country: Italy

Publications

  1. ncbi Macrolide and occult infection in asthma
    Mario Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Curr Opin Pulm Med 10:7-14. 2004
  2. ncbi Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis
    Mario Cazzola
    Department of Pneumology, Unit of Pneumology and Allergology, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
    Pulm Pharmacol Ther 19:30-7. 2006
  3. ncbi Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients
    Mario Cazzola
    Unit of Pneumology and Allergology, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Napoli, Italy
    Pulm Pharmacol Ther 20:258-64. 2007
  4. ncbi The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Respir Med 101:957-62. 2007
  5. ncbi Markers of exacerbation severity in chronic obstructive pulmonary disease
    Luigi G Franciosi
    Leiden Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands
    Respir Res 7:74. 2006
  6. ncbi Immune sensitization of equine bronchus: glutathione, IL-1beta expression and tissue responsiveness
    M G Matera
    Department of Experimental Medicine, 2nd University of Naples, Naples, Italy
    Respir Res 6:104. 2005
  7. ncbi Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD
    M Cazzola
    Department of Pneumology, Unit of Pneumology and Allergology, Antonio Cardarelli Hospital, Milan, Italy
    Pulm Pharmacol Ther 17:121-5. 2004
  8. ncbi Alternative and/or integrative therapies for pneumonia under development
    Mario Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Curr Opin Pulm Med 10:204-10. 2004
  9. ncbi Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Pneumology, A Cardarelli Hospital, Naples, Italy
    Respiration 71:159-64. 2004
  10. ncbi Delivering antibacterials to the lungs: considerations for optimizing outcomes
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Am J Respir Med 1:261-72. 2002

Detail Information

Publications132 found, 100 shown here

  1. ncbi Macrolide and occult infection in asthma
    Mario Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Curr Opin Pulm Med 10:7-14. 2004
    ..These discrepancies highlight the need to define the role, if any, of antimicrobials that are active against atypical pathogens, mainly macrolides, but also tetracyclines and fluoroquinolones, in the treatment of asthma...
  2. ncbi Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis
    Mario Cazzola
    Department of Pneumology, Unit of Pneumology and Allergology, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
    Pulm Pharmacol Ther 19:30-7. 2006
    ....
  3. ncbi Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients
    Mario Cazzola
    Unit of Pneumology and Allergology, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Napoli, Italy
    Pulm Pharmacol Ther 20:258-64. 2007
    ..A direct vasodilatation due to the activation of beta-adrenoceptors that are present in pulmonary vessels is a likely mechanism of their action in inducing the decrease in sPAP...
  4. ncbi The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Respir Med 101:957-62. 2007
    ....
  5. ncbi Markers of exacerbation severity in chronic obstructive pulmonary disease
    Luigi G Franciosi
    Leiden Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands
    Respir Res 7:74. 2006
    ..In an attempt to find the best surrogates for exacerbations, we have reviewed the literature to identify which of these markers change in a consistent manner with the severity of the exacerbation event...
  6. ncbi Immune sensitization of equine bronchus: glutathione, IL-1beta expression and tissue responsiveness
    M G Matera
    Department of Experimental Medicine, 2nd University of Naples, Naples, Italy
    Respir Res 6:104. 2005
    ..We have hypothesized that equine airway sensitization might induce an oxidative stress and increase the ROS production, which in turn might enhance a production of IL-1beta and airway hyperresponsiveness...
  7. ncbi Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD
    M Cazzola
    Department of Pneumology, Unit of Pneumology and Allergology, Antonio Cardarelli Hospital, Milan, Italy
    Pulm Pharmacol Ther 17:121-5. 2004
    ..This study indicates that the addition of budesonide influences the fast onset of action of formoterol, but does not induce systemic effects, in patients with stable COPD...
  8. ncbi Alternative and/or integrative therapies for pneumonia under development
    Mario Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Curr Opin Pulm Med 10:204-10. 2004
    ..Interfering with bacterial adhesion, inhibiting, neutralizing and clearing endotoxin, and administering cytokines as immunoadjuvants are the most promising alternative or integrative treatments for pneumonia that are under development...
  9. ncbi Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Pneumology, A Cardarelli Hospital, Naples, Italy
    Respiration 71:159-64. 2004
    ....
  10. ncbi Delivering antibacterials to the lungs: considerations for optimizing outcomes
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Am J Respir Med 1:261-72. 2002
    ....
  11. ncbi The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, A Cardarelli Hospital, Via del Parco Margherita 24, Naples 80121, Italy
    Pulm Pharmacol Ther 17:35-9. 2004
    ..Since tiotropium ensures prolonged bronchodilation, whereas formoterol adds fast onset and a greater peak effect, the two drugs appear complementary...
  12. ncbi Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD
    Mario Cazzola
    Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 16:197-201. 2003
  13. ncbi Safety of long-acting beta2-agonists in the treatment of asthma
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Ther Adv Respir Dis 1:35-46. 2007
    ..Patients with asthma should be initiated and maintained on sufficiently high doses of ICSs and only patients whose asthma cannot be controlled should receive additional LABAs on a regular basis...
  14. ncbi Novel approaches to the treatment of pneumonia
    Mario Cazzola
    Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Via del Parco Margherita 24, 80121 Napoli, Italy
    Trends Pharmacol Sci 24:306-14. 2003
    ..The challenge is to optimize and develop these agents to provide novel approaches to the treatment of pneumonia in hospitalized patients...
  15. ncbi Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
    Pulm Pharmacol Ther 16:131-45. 2003
    ..Obviously, these antibiotics must be reserved only to cases of documented ineffectiveness of the common antimicrobial agents...
  16. ncbi A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD
    M Cazzola
    Dipartimento di Medicina Respiratoria, Azienda Ospedaliera di Rilevanza Nazionale A Cardarelli, Unità Complessa di Pneumologia e Allergologia, Napoli, Italy
    Respir Med 97:458-62. 2003
    ..Also they did not influence SpO2. This study indicates that a single high dose offormoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD...
  17. ncbi Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 97:453-7. 2003
    ..The results indicate that an inhaled combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid appears to be effective in improving airway limitation after acute administration in patients suffering from COPD...
  18. ncbi Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Second University of Naples, Via del Parco Margherita 24, 80121 Naples, Italy
    Pulm Pharmacol Ther 16:105-9. 2003
    ..001) from 2-h levels. These results show that dose-dependent bronchodilatation of formoterol is maintained despite regular treatment...
  19. ncbi Have guidelines for the management of community-acquired pneumonia influenced outcomes?
    M Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 97:205-11. 2003
  20. ncbi Asthma treatment must be always tailored to the individual patient
    M Cazzola
    U O S C di Pneumologia e Allergologia, Dipartimento di Pneumologia, A O R N A Cardarelli, Napoli, Italy
    Monaldi Arch Chest Dis 57:213-7. 2002
    ....
  21. ncbi Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD
    Mario Cazzola
    Respiratory Medicine and Allergology Unit, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
    Pulm Pharmacol Ther 17:141-5. 2004
    ....
  22. ncbi Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, Antonio Cardarelli Hospital, Naples, Italy
    Chest 126:220-37. 2004
    ..All of these effects are very important because, despite recent advances in our understanding of COPD and its treatment, therapy remains suboptimal for a considerable number of patients...
  23. ncbi Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 22:177-82. 2009
    ....
  24. ncbi The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD
    Mario Cazzola
    Antonio Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Int J Chron Obstruct Pulmon Dis 1:345-54. 2006
    ..However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting beta2-agonist alone...
  25. ncbi [Adequate surrogate parameters in COPD studies]
    M Cazzola
    Dipartimento di Medicina, Interna, , Via Montpellier 1, 00133 Roma, Italy
    Dtsch Med Wochenschr 132:522-3. 2007
  26. ncbi A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Pulm Pharmacol Ther 20:556-61. 2007
    ..Our results suggest that adding FSC and tiotropium may provide benefits in symptomatic patients with severe-to-very severe stable COPD...
  27. ncbi Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis
    Mario Cazzola
    Department of Pneumology, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Chest 128:2093-8. 2005
    ....
  28. ncbi Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease
    Mario Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
    Expert Opin Investig Drugs 14:775-83. 2005
    ..The only limits set for the development of a LABA with a new product profile are medical needs and marketing opportunities...
  29. ncbi Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD
    M Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, Antonio Cardarelli Hospital, Naples, Italy
    Respir Med 100:212-7. 2006
    ..Patients with severe chronic airway obstruction might suffer dangerous hypoxemia after administration of a beta-agonist despite bronchodilation...
  30. ncbi Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae
    Mario Cazzola
    Department of Pneumology, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Respir Med 99:663-9. 2005
    ..This finding allows the use of antibiotics such as azithromycin, which, otherwise, should be avoided because of resistances...
  31. ncbi Inflammation--a new therapeutic target in pneumonia
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Respiration 72:117-26. 2005
    ..We believe that compounds capable of stimulating early host defense and microbial clearance, but not the later phases of inflammatory tissue injury associated with sepsis, may be advantageous...
  32. ncbi Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients
    Mario Cazzola
    Antonio Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 99:524-8. 2005
    ..Differences between the two treatments were not statistically significant (P>0.05). The addition of second different long-acting bronchodilator to a regularly administered long-acting bronchodilator seems to be to patient's advantage...
  33. ncbi Novel approaches to the treatment of bacterial lower respiratory tract infections: introduction
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, A. Cardarelli Hospital, Naples, Italy
    Respiration 72:7-8. 2005
  34. ncbi The functional impact of adding salmeterol and tiotropium in patients with stable COPD
    M Cazzola
    Department of Respiratory Medicine, Antonio Cardarelli Hospital, Via del Parco Margherita 24, Napoli 80121, Italy
    Respir Med 98:1214-21. 2004
    ....
  35. ncbi Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD
    M Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Naples, Italy
    Respir Med 96:790-5. 2002
    ..11 (95% CI: -1.00 to 0.79)] did not change significantly from baseline (P > 0.05). These data indicate that salmeterol is effective and safe in the treatment of acute exacerbation of COPD and support its use in this clinical condition...
  36. ncbi Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Respir Med 96:439-43. 2002
    ....
  37. ncbi Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study
    M Cazzola
    Divisione di Pneumologia ed Allergologia e Settore di Farmacologia Clinica Respiratoria, AORN A Cardarelli, Napoli, Italy
    J Chemother 13:407-12. 2001
    ....
  38. ncbi Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD
    M Cazzola
    lt lt S Maugeri Foundation, Institute of Care and Research, Veruno Medical Centre of Rehabilitation, Veruno NO, Italy
    Pulm Pharmacol Ther 12:267-71. 1999
    ..5%). Significant improvement in pulmonary function may be achieved by giving two different bronchodilators in stable COPD patients. The sequence formoterol 24 microg + oxitropium bromide 200 microg seems to be the most effective...
  39. ncbi Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
    M Cazzola
    Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 14:41-5. 2001
    ..Again, there was no significant difference (P= 0.817) between the four active treatments. Formoterol Turbuhaler 12 microg and 24 microg caused bronchodilation as rapidly as salbutamol 400 microg and 800 microg given via pMDI...
  40. ncbi Additive effects of salmeterol and fluticasone or theophylline in COPD
    M Cazzola
    A Cardarelli Hospital, Division of Pneumology and Allergology and Respiratory Clinical Pharmacology Unit, Naples, Italy
    Chest 118:1576-81. 2000
    ..ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD...
  41. ncbi Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma
    M Cazzola
    Divisione di Pneumologia e Allergologia, Ospedale A Cardarelli, Napoli, Italy
    Chest 118:1322-6. 2000
    ....
  42. ncbi Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Clin Ther 24:595-604. 2002
    ....
  43. ncbi Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist
    M Cazzola
    Divisione di Pneumologia e Allergologia e Unità di Farmacologia Clinica Respiratoria, Ospedale A Cardarelli, Naples, Italy
    Pulm Pharmacol Ther 13:301-5. 2000
    ....
  44. ncbi Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance
    M Cazzola
    Division of Pneumology and Allergology and Respiratory Clinical Pharmacology Unit, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 13:249-56. 2000
    ....
  45. ncbi 5-HT modifiers as a potential treatment of asthma
    I Cazzola
    Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
    Trends Pharmacol Sci 21:13-6. 2000
    ..Accordingly, modifiers of the 5-HT transmitter system such as compounds that affect the 5-HT transporter, prejunctional 5-HT receptors or postsynaptic 5-HT receptors might represent a novel treatment of asthma...
  46. ncbi Novel oral cephalosporins
    M Cazzola
    Department of Respiratory Medicine, Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A Cardarelli Hospital, Naples, Italy
    Expert Opin Investig Drugs 9:237-46. 2000
    ..Perhaps with such an approach, the perceived need for new cephalosporins will diminish...
  47. ncbi Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD
    M Cazzola
    A Cardarelli Hospital, Division of Pneumology and Allergology, Naples, Italy
    Respir Med 93:909-11. 1999
    ..In any case, formoterol 24 microg alone seems sufficient to achieve the same bronchodilation induced by oxitropium 600 microg alone in most patients...
  48. ncbi Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis
    M Cazzola
    Ospedale A Cardarelli, Divisione di Pneumologia e Allergologia e Unità di Farmacologia Clinica Respiratoria, Napoli, Italy
    J Chemother 12:216-22. 2000
    ..Therefore, it might be considered for first choice treatment of acute exacerbations of chronic bronchitis...
  49. ncbi Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease
    M Cazzola
    A Cardarelli Hospital, Division of Pneumology and Allergology, Naples, Italy
    Drugs 60:307-20. 2000
    ....
  50. ncbi Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
    M Cazzola
    Divisione di Pneumologia e Allergologia and the Settore di Farmacologia Clinica Respiratoria, Ospedale A Cardarelli, Napoli, Italy
    Chest 114:411-5. 1998
    ....
  51. ncbi Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction
    M Cazzola
    Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 15:97-102. 2002
    ..559) and 15 min (Group A: P=0.526; Group B: P=0.818) post dose. No adverse events were reported during the study. Formoterol Turbuhaler has as rapid an onset of action as salbutamol pMDI when given at the recommended doses...
  52. ncbi Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections
    M Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Naples, Italy
    Pulm Pharmacol Ther 14:367-81. 2001
    ....
  53. ncbi Clinical pharmacokinetics of salmeterol
    Mario Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Clin Pharmacokinet 41:19-30. 2002
    ..This is an important point, because it has been demonstrated that the systemic effects of salmeterol are more likely to occur with higher doses, which lead to approximately proportionally increased blood concentrations...
  54. ncbi The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction
    Mario Cazzola
    Dipartimento di Pneumologia, Unità Operativa Complessa di Pneumologia ed Allergologia, Ospedale A Cardarelli, Napoli, Italy
    Chest 121:230-41. 2002
    ..For patients who are unresponsive to the aforementioned drugs, AT(1) receptor antagonists, newer beta(1)-adrenoceptor-blocking agents with ancillary properties (eg, celiprolol or nebivolol), and/or vasodilators can be considered...
  55. ncbi Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD
    M Cazzola
    Ospedale A Cardarelli, Dipartimento di Pneumologia, U O di Pneumologia e Allergologia, Napoli, Italy
    Respir Med 95:917-21. 2001
    ..Results of this study suggest the use of higher than customary dose of formoterol for as-needed therapy to provide rapid relief of bronchospasm in patients suffering from acute exacerbations of partially reversible COPD...
  56. ncbi Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease
    M Cazzola
    Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A Cardarelli Hospital, Naples, Italy
    Respiration 68:452-9. 2001
    ..It has been suggested that the effect of a beta2-agonist is additive with that of a cysteinyl leukotriene 1 receptor antagonist...
  57. ncbi Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation
    P Santus
    Respiratory Medicine Unit, San Paolo Hospital, University of Milan, Milan, Italy
    Respir Med 100:1277-81. 2006
    ....
  58. ncbi Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD
    F di Marco
    University of Milan, San Paolo Hospital, Respiratory Unit, Milan, Italy
    Eur Respir J 21:86-94. 2003
    ..The potential advantage of formoterol needs to be tested in a larger patient population...
  59. ncbi Azithromycin and lower respiratory tract infections
    F Blasi
    Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Policlinico Mangiagalli Regina Elena, Milan, Italy
    Expert Opin Pharmacother 6:2335-51. 2005
    ..In addition, pharmacokinetic and pharmacodynamic properties of the drug are also considered...
  60. ncbi Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis
    M Cazzola
    S Maugeri Foundation, Institute of Care and Research, Medical Center of Rehabilitation, Clinical Pharmacology Unit and Respiratory Pharmacology Center, Veruno NO, Italy
    J Chemother 11:119-25. 1999
    ..2%) in the azithromycin group. We conclude that dirithromycin and azithromycin appear to be equally effective in the treatment of acute bacterial exacerbations of chronic bronchitis...
  61. ncbi Psychometric properties of the Fibromyalgia Assessment Status (FAS) index: a national web-based study of fibromyalgia
    C Iannuccelli
    La Sapienza University, Rome, Italy
    Clin Exp Rheumatol 29:S49-54. 2011
    ..Both questionnaires may be useful when screening FM patients, with the choice of the most appropriate instrument depending on the setting...
  62. ncbi An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses
    M G Matera
    Unit of Pharmacology, Department of Experimental Medicine, Second University of Naples, Naples, Italy
    Respiration 72:466-70. 2005
    ..Therefore, they question the direct therapeutic relevance of a subdivision of patients according to bronchodilator responses to tiotropium or salmeterol...
  63. ncbi General strategy for the management of bronchial asthma in pregnancy
    G Liccardi
    Unit of Pneumology and Allergology, Department of Chest Diseases, A Cardarelli Hospital, Piazza Arenella no 7 h, Naples 80128, Italy
    Respir Med 97:778-89. 2003
    ..We herein review and discuss the available data and the criteria for the management of asthma in pregnant patients...
  64. ncbi Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma
    S Centanni
    Respiratory Disease Unit, University of Milan, San Paolo Hospital, Milan, Italy
    Respiration 67:60-4. 2000
    ..The present study was designed to assess the non-pulmonary effects of a 2-week treatment with the addition of formoterol to budesonide therapy in 10 patients with mild or moderate asthma...
  65. ncbi A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease
    M Cazzola
    Respiratory Clinical Pharmacology Unit, A Cardarelli Hospital, Naples
    J Chemother 9:279-84. 1997
    ..Notwithstanding its poor in vitro activity against H. influenzae, dirithromycin was fairly active against this microorganism in vivo...
  66. ncbi Cefaclor in the treatment of infective exacerbations of chronic bronchitis in cigarette smokers
    M Cazzola
    36th Division of Pneumology and Respiratory Allergy, A Cardarelli Hospital, Naples, Italy
    J Chemother 3:245-9. 1991
    ..Because of its excellent response rate, cefaclor is of particular value in the treatment of lower respiratory tract infections in cigarette smokers...
  67. ncbi Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, Antonio Cardarelli High Specialty Hospital, Naples, Italy
    Pulm Pharmacol Ther 19:79-89. 2006
    ....
  68. ncbi Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers
    Franco Pasqua
    Pulmonary Rehabilitation, IRCCS San Raffaele, Velletri, Rome, Italy
    Ther Adv Respir Dis 2:209-14. 2008
    ..pneumoniae (2 out of 10), S. aureus (1 out of 8), M. catarrhalis (1 out of 7), and P. aeruginosa (1 out of 3). This study seems to indicate that prulifloxacin is of particular value in the treatment of AECOPD in cigarette smokers...
  69. ncbi Primary care of the patient with chronic obstructive pulmonary disease in Italy
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Diseases, University of Rome Tor Vergata, Rome, Italy
    Respir Med 103:582-8. 2009
    ..It must also be noted that, in general, patients with COPD are undertreated...
  70. ncbi Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone
    Mario Cazzola
    Department of Internal Medicine, University Tor Vergata, Rome, Italy
    Ther Adv Respir Dis 3:59-63. 2009
    ..This study investigated the value of adding Ismigen, a polyvalent mechanical bacterial lysate, to therapy of COPD patients (FEV(1) <60% predicted) under regular treatment with salmeterol/fluticasone (SFC)...
  71. ncbi Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function
    Mario Cazzola
    Division of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    COPD 6:404-15. 2009
    ..Once-daily or twice-daily formoterol, added to tiotropium, are both better than tiotropium alone, but the published evidence suggests twice-daily formoterol is the best add-on option...
  72. ncbi Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists
    Pierachille Santus
    Unit of Respiratory Medicine, University of Milan, S Paolo Hospital, Milan, Italy
    Respir Med 101:1798-803. 2007
    ..Since the three agents were similar in inducing bronchodilation, we believe that tiotropium is preferable in patients with hypoxemia caused by stable COPD because it seems to carry a smaller risk of worsening systemic hypoxemia...
  73. ncbi Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma
    Alessandro Vatrella
    Section of Respiratory Diseases, Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy
    Pulm Pharmacol Ther 18:89-92. 2005
    ....
  74. ncbi Roflumilast in chronic obstructive pulmonary disease: evidence from large trials
    Mario Cazzola
    Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina Interna, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Expert Opin Pharmacother 11:441-9. 2010
    ..At present roflumilast is the most advanced PDE-4 inhibitor undergoing clinical trials for COPD...
  75. ncbi Novel long-acting bronchodilators for COPD and asthma
    M Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Br J Pharmacol 155:291-9. 2008
    ..The advent of a successful MABA product will revolutionize the field and open the door for a new range of combination products...
  76. ncbi Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
    Andrea Rossi
    Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy
    Int J Chron Obstruct Pulmon Dis 3:521-9. 2008
    ..Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome...
  77. ncbi Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy
    Drugs 65:1595-610. 2005
    ..Therefore, beta(2)-agonists must always be used with caution in patients with cardiopathies because these agents may precipitate the concomitant cardiac disease...
  78. ncbi ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
    Maria Gabriella Matera
    Department of Experimental Medicine, Unit of Pharmacology, 2nd University of Naples, Naples, Italy
    Drugs 67:503-15. 2007
    ....
  79. ncbi Treating systemic effects of COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Trends Pharmacol Sci 28:544-50. 2007
    ..Nonetheless, initial data seem to indicate that drugs, such as statins, ACE inhibitors, AT1 receptor blockers and PPAR agonists, used to treat a co-morbid condition have the potential to benefit COPD patients...
  80. ncbi A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 22:522-5. 2009
    ..However, these methods are not interchangeable. In moderate-to-severe airflow obstruction, dilution method tends to underestimate and body plethysmography tends to overestimate RV...
  81. ncbi Outcomes for COPD pharmacological trials: from lung function to biomarkers
    M Cazzola
    Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Eur Respir J 31:416-69. 2008
    ..Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations...
  82. ncbi Outdoor air pollution, climatic changes and allergic bronchial asthma
    G D'Amato
    Division of Pneumology and Allergology, Azienda Ospedaliera ad Alta Specialità A Cardarelli, Napoli, Italy
    Eur Respir J 20:763-76. 2002
    ..As a consequence, an enhanced immunoglobulin E-mediated response to aeroallergens and enhanced airway inflammation favoured by air pollution could account for the increasing prevalence of allergic respiratory diseases in urban areas...
  83. ncbi Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing
    G W Canonica
    Clinica di Malattie dell Apparato Respiratorio e Allergologia, DIMI, Universita degli Studi di Genova, Padiglione Maragliano, Largo Rosanna Benzi, 10 16132 Genova, Italy
    Pulm Pharmacol Ther 17:239-47. 2004
    ..In conclusion, adjustable maintenance dosing with budesonide/formoterol effectively controls asthma at a reduced drug load with lower costs than fixed maintenance dosing...
  84. ncbi Respiratory allergic diseases induced by outdoor air pollution in urban areas
    G D'Amato
    Division of Pneumology and Allergology, Department of Chest Diseases, Azienda Ospedaliera ad Alta Specialità A Cardarelli, 80121 Napoli, Italy
    Monaldi Arch Chest Dis 57:161-3. 2002
    ..However, air pollution and climatic changes may also have an indirect effect on the allergic response by influencing quantitatively and qualitatively the pollen production of allergenic plants...
  85. ncbi The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy
    G D'Amato
    Division of Pneumology and Allergology, Azienda Ospedaliera ad Alta Specialità A Cardarelli, Napoli, Italy
    Respir Med 95:606-11. 2001
    ..Several factors influence this interaction, including type of air pollutants, plant species, nutrient balance, climatic factors, degree of airway sensitization and hyperresponsiveness of exposed subjects...
  86. ncbi Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis
    M Cazzola
    Divisione di Pneumologia ed Allergologia, Ospedale A Cardarelli, Napoli, Italy
    J Chemother 7:432-41. 1995
    ..However, co-amoxiclav demonstrated a higher efficacy rate than cefixime and ciprofloxacin and was better tolerated. Therefore, it can be used as a first-choice drug in the treatment of exacerbation of chronic bronchitis...
  87. ncbi TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water
    Maria Gabriella Matera
    Second University of Naples, Department of Experimental Medicine, Unit of Pharmacology and Toxicology, Naples, Italy
    Pulm Pharmacol Ther 23:121-8. 2010
    ....
  88. ncbi The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 23:257-67. 2010
    ....
  89. ncbi Arformoterol tartrate in the treatment of COPD
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Expert Rev Respir Med 4:155-62. 2010
    ....
  90. ncbi Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases
    Gennaro D'Amato
    Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Speciality Hospital A Cardarelli, Naples, Italy
    Curr Drug Targets Inflamm Allergy 3:227-9. 2004
    ....
  91. ncbi Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 102:1425-30. 2008
    ....
  92. ncbi Novel bronchodilators in asthma
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome Tor Vergata, Rome, Italy
    Curr Opin Pulm Med 16:6-12. 2010
    ..Because of the central role of bronchodilators in the treatment of asthma, in recent years there has been a renewed interest in the field and now once-daily bronchodilators are in development in an attempt to simplify their use...
  93. ncbi Indacaterol for chronic obstructive pulmonary disease (COPD)
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rehabilitative Pneumology, IRCCS, San Raffaele Pisana, Rome, Italy
    Drugs Today (Barc) 46:139-50. 2010
    ..The rapid onset of action of indacaterol, duration of bronchodilation for at least 24 hours, and an optimal safety profile make this drug an interesting and attractive weapon for its use in fight against the COPD...
  94. ncbi It's about time--directing our attention toward modifying the course of COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Respir Med 102:S37-48. 2008
    ..In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy...
  95. ncbi Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction
    Cecilia Calabrese
    Department of Cardio Thoracic and Respiratory Sciences, Second University of Naples, Monaldi Hospital, Via Bianchi, 80131 Naples, Italy
    Respir Med 100:1415-22. 2006
    ....
  96. ncbi Pulmonary penetration of ceftazidime
    M Cazzola
    Institute of Pharmacology and Toxicology, Medical School, Second Neapolitan University, Naples, Italy
    J Chemother 7:50-4. 1995
    ..38, 8.14 +/- 2.23, 6.40 +/- 1.63, 4.06 +/- 0.99 and 0.45 +/- 0.27 microgram/g) were higher than that in BS (6.87 +/- 1.96, 6.54 +/- 1.84, 3.52 +/- 1.23, 1.56 +/- 0.92 and 0.23 +/- 0.19 microgram/ml).(ABSTRACT TRUNCATED AT 250 WORDS)..
  97. ncbi Telithromycin in lower respiratory tract infections
    F Blasi
    University of Milan, Institute of Respiratory Diseases, IRCCS Ospedale Maggiore Milano, Milan, Italy
    Future Microbiol 1:7-16. 2006
    ..In addition, pharmacokinetic and pharmacodynamic properties of the drug are considered...
  98. ncbi Clinical pharmacokinetics of theophylline during co-treatment with ticarcillin plus clavulanic acid in patients suffering from acute exacerbation of chronic bronchitis
    M G Matera
    Institute of Pharmacology and Toxicology, Medical School, Second University, Naples, Italy
    J Chemother 5:233-6. 1993
    ..No influence of ticarcillin/clavulanic acid was detectable on the steady-state theophylline pharmacokinetics. It is concluded that both drugs can be administered concomitantly without any dosage adjustment of theophylline...
  99. ncbi Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Respiratory Disease Unit, Via Montpellier 1, I 00133 Rome, Italy
    Curr Opin Investig Drugs 10:482-90. 2009
    ....
  100. ncbi Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 102:321-7. 2008
    ..Moreover, the method of inactivation can affect the immunogenicity of essential antigens through denaturation. For this reason, the efficacy of bacterial immunostimulants should not only be assessed but also compared...
  101. ncbi Long-acting beta(2) agonists in asthma and allergic rhinitis
    Maria Gabriella Matera
    2nd University of Naples, Department of Experimental Medicine, Naples, Italy
    Expert Opin Pharmacother 9:1531-9. 2008
    ..This is quite surprising given that there is now clear documentation of the link between asthma and allergic rhinitis...